BRAF and metastatic melanoma: Taking these findings into account, we believe that repeated screening of BRAFV600E status using VE1 antibody is important when a new metastatic melanoma occurs in patients with previously BRAF mutation-negative melanoma; this screening helps ensure that physicians do not overlook patients who are eligible for BRAF inhibitor treatment.